CTLA4 and colitis: Colitis of any grade, which most commonly presents with diarrhea, has been reported in 30-40% of patients treated with ipilimumab, while severe colitis/diarrhea is seen in up to 7.6-17% patients on anti-CTLA4 treatment (32, 33) (Table 1).